[The result of VIP chemotherapy as an induction therapy in 6 patients with non-seminomatous extragonadal germ cell tumor].
We treated 6 patients with non-seminomatous extragonadal germ cell tumor (NSEGCT) by VP-16 + ifosfamide + cisplatin (VIP) chemotherapy as an induction therapy to investigate the effectiveness and safety. Primary lesions were located at the mediastinum in 4 patients and the retroperitoneum in 2 patients. As a rule, all patients were treated with VIP chemotherapy of 4 courses with or without second-line treatment such as chemotherapy, residual tumor resection and/or radiation. Following the induction therapy (VIP), 4 of 6 patients (67%) achieved complete or partial responses. After salvage therapy, 4 patients (67%) achieved complete responses and two other patients also achieved partial responses. However, only 2 of the 5 patients who had been follow-up for more than 2 years have remained disease free. The effects of VIP chemotherapy on non-seminomatous extragonadal germ cell tumor appeared to be similar to those of the conventional chemotherapies though the number of patients was small in the current study. It appears to be necessary to design more effective regimen.
Sakura
Mizuaki
M
Tsukamoto
Tetsurou
T
Yonese
Junji
J
Nakaishi
Masayuki
M
Ohkubo
Yuhei
Y
Maezawa
Takuya
T
Takimoto
Keita
K
Fukui
Iwao
I
Nakagawa
Ken
K
Okumura
Sakae
S
Ishikawa
Yuichi
Y
Aoki
Nozomu
N
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin; D005047:Etoposide; D018237:Germinoma / Q000188:drug therapy*; D006801:Humans; D007069:Ifosfamide; D008297:Male; D008875:Middle Aged; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy*; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies
D005047:Etoposide; D002945:Cisplatin; D007069:Ifosfamide